Order Code BRBST Tickborne Bacterial, PCR and Sequencing, Blood
Necessary Information
Specimen source is required.
Specimen Required
Container/Tube:
Preferred: Lavender top (EDTA)
Acceptable: Royal blue top (EDTA), pink top (EDTA), or sterile vial containing EDTA-derived aliquot
Specimen Volume: 1 mL
Collection Instructions: If not submitting in original vial, mix well before transferring to a sterile vial.
Useful For
Detecting and identifying pathogenic tickborne bacteria infecting normally sterile whole blood
Potential detection of bacteria that cause similar illnesses to tickborne infections
This test should not be used as first tier test. It should only be used when routine testing is negative.
This test is not recommended as a test of cure because nucleic acids may persist for long periods of time after successful treatment.
Reflex Tests
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
SPID2 | Specimen Identification by PCR | No, (Bill Only) | No |
Testing Algorithm
For information see Acute Tickborne Disease Algorithm.
Special Instructions
Method Name
16S Ribosomal RNA Gene Polymerase Chain Reaction (PCR) followed by Next Generation Sequencing (NGS)
Reporting Name
Tickborne Bacterial PCR+Sequence, BSpecimen Type
Whole Blood EDTASpecimen Minimum Volume
0.5 mL
Specimen Stability Information
Specimen Type | Temperature | Time |
---|---|---|
Whole Blood EDTA | Refrigerated (preferred) | 14 days |
Frozen | 14 days |
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Reference Values
No tickborne bacterial DNA detected
Method Description
The test utilizes DNA extraction from EDTA whole blood and polymerase chain reaction (PCR) of a highly variable fragment of the 16S ribosomal RNA (rRNA) gene. If present, the amplified DNA is sequenced to obtain identification of the source organism from the patient sample. Specimens undergo total nucleic acid extraction, and the purified eluate is produced by the MP96 (Roche Diagnostics). The DNA eluate is concentrated two-fold from the specimen input volume. PCR is performed on a LightCycler 480II instrument (Roche Diagnostics) to amplify approximately 530 base pairs (bp) of the bacterial 16S rRNA gene (V1-V3, exact length varies by species) with SYBR Green DNA detection.
Amplification inhibition is detected with a second PCR reaction performed using the extracted specimen spiked with a low concentration of positive control DNA. Due to high crossing point values reflecting the low abundance of pathogens, all patient samples for this test will undergo next-generation sequencing (NGS).
Samples are sequenced using NGS on a MiSeq sequencing platform (Illumina). The NGS process generates 500 bases of sequencing reads (250 bp in the forward and reverse directions). Due to the size of amplicon generated, there is a gap in coverage between forward and reverse sequences. Verification results and in silico analysis have demonstrated that forward sequence results (≥210 bp) offer the same bacterial identity as full-length amplicon sequence for all organisms that can be reported by this assay. Quality filtering and results generation from NGS files is performed with Pathogenomix cloud-based software (RipSeq NGS).
High-quality sequence (Q ≥30) of 210 bp or more in length are sorted into clusters based on the observed sequence and used for identification. Positive and negative controls are used throughout all processes to ensure assay performance. Forward and reverse sequences are analyzed to determine bacterial identity using the cloud-based analysis program RipSeq NGS (Pathogenomix).(Rodino KG, Wolf MJ, Sheldon S, et al. Detection of tick-borne bacteria from whole blood using 16S ribosomal RNA gene PCR followed by next-generation sequencing. J Clin Microbiol. 2021;59(5):e03129-20. doi:10.1128/JCM.03129-20)
Day(s) Performed
Monday through Friday
Performing Laboratory

CPT Code Information
87801-Broad Range Bacterial PCR and Sequencing
87798-Specimen Identification by PCR (if appropriate)